Navigation Links
Nektar Therapeutics Reports Third Quarter 2009 Financial Results
Date:11/4/2009

- --- ---- --- Net loss $(30,967) $(37,038) $(94,843) $(111,118) ======== ======== ======== ========= Basic and diluted net loss per share $(0.33) $(0.40) $(1.02) $(1.20) Shares used in computing basic and diluted net loss per share 92,789 92,425 92,621 92,413 NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (unaudited) ASSETS September 30, 2009 December 31, 2008 (1) ------------------ ----------------- Current assets: Cash and cash equivalents $32,777 $155,584 Short-term investments 242,901 223,410 Accounts receivable, net of allowance 6,330 11,161 Inventory 8,930 9,319 Other current assets 7,275 6,746 ----- ----- Total current assets $298,213 $406,220 Property and equipment, net 74,624 73,578 Goodwill 76,501 76,501 Other assets 3,313 4,237 ----- ----- Total assets $452,651 $560,536 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $6,397 $13,832 Accrued compensation 9,711 11,570 Accrued clinical trial expens
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
3. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
4. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
5. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. Nektar Therapeutics Reports First Quarter 2009 Financial Results
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
11. Nektar Announces Retirement of Irwin Lerner from Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... World,s Top Gene Synthesis Companies...C) to Coordinate Best Practices in Risk Reduction ...orldwide Gene Synthesis Capacity , ... world’s leading gene synthesis companies to...mon screening protocol to promote biosecurity in t...
(Date:11/18/2009)...at the National Institute of Standards and Technol...nexpensive method for detecting and measuring elus...s, invisible spoilage in food or pesticides distri...od is more sensitive than conventional techniques ... polarlike water molecules, having distinct electr...
(Date:11/18/2009)...RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ -...nced today that data from the University of Pennsy... of Sangamo,s zinc finger nuclease (ZFN) based pro...d prematurely disclosed on the internet. ,, Dat...sity of Pennsylvania School of Medicine from a sin...
(Date:11/18/2009)..., NEW YORK, Nov. 18 Reportlinker...s available in its catalogue. ,, Biotechnolog... http://www.reportlinker.com/p0164375/Biotechnolog...source=prnewswire&utm_medium=pr&utm_campai...gy are complex chemical compounds used in a range ...
Breaking Biology Technology:World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4Prototype NIST method detects and measures elusive hazards 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 2Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 3Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 4Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 5Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 6Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 7Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 8
... July 1 Microfluidic Systems Inc.,(MFSI) announce...ement for,the production of Microfluidic - Bioagen...rd is the fourth in a series of funded phases by t...03. The continued funding,through March 2009, will...ems for extended field trials in key locations aro...
...ly 1 The Delaware Valley,Innovation Network (DVIN...n,Investment Grant. The Wistar Institute will rece...ician Training (BTT) Program, a two-year workforce...al research., The BTT Program provides Community ... and hands-on experience training while preparing ...
...ly 1 Healthation, a healthcare,technology company...n Third,Party Administrator (TPA) to a 10 year con...al-time, rules-based AcceleHealth(R) benefits and ...Portal to deliver interactive,self-service capabil... and,pharmacy lines of business., They will imple...
Other Biology Technology:Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 2Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 3Delaware Valley Innovation Network Awards First Innovation Investment Grant to the Wistar Institute 2Delaware Valley Innovation Network Awards First Innovation Investment Grant to the Wistar Institute 3Healthation Chosen by Large Canadian Third Party Administrator to Support All Employee Benefits and Claims Administration 2
(Date:11/20/2009)...single bacterial gene into yeast, researchers from... achieved three improvements in bioethanol product...l, less acetate and elimination of the major by-pr...hed in the scientific journal Applied and Environ...l is made by the yeast Saccharomyces cerevisiae fr...
(Date:11/20/2009)...in German . , In the current online issue o...fanie Eyerich and Dr. Kilian Eyerich together with... Istituto Dermopatico dell,Immacolata in Rome, pre... a milestone on the way to developing new treatmen...soriasis and allergic reactions and potentially al...
(Date:11/20/2009)...ry disease (COPD), a respiratory disease commonly ...ourth leading cause of death worldwide. 600 milli...e yet to find any real treatment or cure, Grace Pa...ity of Western Ontario in London, Canada, is using...to the disease. , Parraga is a scientist in ...
Breaking Biology News(10 mins):Delft breakthrough in bioethanol production from agricultural waste 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Gaining a better picture of lung disease 2Emerging Washington State Health Care Model Secures 247 5 Million in Venture Capital 50894 1Emerging Washington State Health Care Model Secures 247 5 Million in Venture Capital 50894 2Emerging Washington State Health Care Model Secures 247 5 Million in Venture Capital 50894 3Emerging Washington State Health Care Model Secures 247 5 Million in Venture Capital 50894 4Emerging Washington State Health Care Model Secures 247 5 Million in Venture Capital 50894 5Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics 50892 1Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics 50892 2CareFusion Files Amended Form 10 Registration Statement With SEC 50890 1CareFusion Files Amended Form 10 Registration Statement With SEC 50890 2CareFusion Files Amended Form 10 Registration Statement With SEC 50890 3
...MES, Iowa -- Iowa State University researcher Robe...ins have controlled motions. , Most biochemists ...ncontrolled movements. , Research conducted by Je...nformatics and Biological Statistics together with...ience and graduate student Lei Yang, over a 10-yea...
...uergen Tautz from the University of Wuerzburg will... the 2008 EMBO Award for Communication in the Life...tion (EMBO) awards the prize annually to a practic...ion with the public. The additional award was made...ication activity on a single organism using all av...
...he Ecological Society of America today criticized ...terpret the Endangered Species Act, which would im...t for federal projects to undergo independent scie...encies to decide for themselves whether their proj..."The concept of independent scientific review has ...
Other Biology News:Iowa State University researcher shows proteins have controlled motions 2EMBO recognizes German zoologist for public communication 2Ecological Society of America criticizes administration's overhaul of the Endangered Species Act 2
Mouse Anti-Human Acetylcholinesterase, brain (AChE) Monoclonal Antibody, Unconjugated, Clone 12B4 from AntibodyShop A/S
...sed to study co-translational and initial post-tra...ts such as signal peptide cleavage, membrane inser...examined by the translation of the appropriate mRN...branes. In addition, processing and glycosylation ...
Mouse Anti-Polio component type I Monoclonal Antibody, Unconjugated, Clone 9B4 from AntibodyShop A/S
Mouse Anti-Glucagon-like peptide-1 (GLP-1 (1-36) amide) Monoclonal Antibody, Unconjugated, Clone 9F8 from AntibodyShop A/S
Biology Products: